Apellis Pharmaceuticals, Inc. (APLS) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.66. This compares to loss of $1.50 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.61%. A quarter ago, it was expected that this company would post a loss of $0.84 per share when it actually produced a loss of $1.17, delivering a surprise of -39.29%.Over the last four quarters, the comp ...

Fourth Quarter and Full Year 2023 Financial Results Conference Call Apellis Participants CEDRI C F RANCO I S, M. D. , Ph . D. Co-Founder, President & Chief Executive Officer ...

Generated $397 million in full year 2023 revenues, including $275 million for SYFOVRE® (pegcetacoplan injection) and $91 million for EMPAVELI® (pegcetacoplan)Strong SYFOVRE launch, with more than 160,000 total doses (commercial and samples) distributed in 2023 Topline data from Phase 3 VALIANT study of systemic pegcetacoplan in C3G and IC-MPGN expected in mid-2024Cash and cash equivalents of $351 million as of December 31, 2023 WALTHAM, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38276 | --- | --- | --- | |---------------------------------------------------------------------------------------|------------------ ...

We are in the last week of the fourth-quarter 2023 earnings season. Results are, so far, much better than expected. As of Feb 20, 402 companies on the S&P 500 Index have reported their financial numbers. Total earnings for these index members are up 4.9% from the same period last year on 3.4% higher revenues, with 78.6% beating EPS estimates and 64.4% beating revenue estimates.At present, total earnings of the S&P 500 Index in fourth-quarter 2023 are expected to be up 5.5% on 3.2% higher revenues. This woul ...

WALTHAM, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc., (NASDAQ:APLS) today announced that the company will participate in the following March investor conferences: TD Cowen 44th Annual Healthcare Conference: Fireside chat on Monday, March 4, 2024, at 2:10 p.m. ETOphthalmology Corporate Panel Discussion on Tuesday, March 5, 2024, at 9:10 a.m. ET Raymond James & Associates' 45th Annual Institutional Investors Conference: Fireside chat on Tuesday, March 5, 2024, at 11:00 a.m. ET The l ...

Investors are always looking for stocks that are poised to beat at earnings season and Apellis Pharmaceuticals, Inc. (APLS) may be one such company. The firm has earnings coming up pretty soon, and events are shaping up quite nicely for their report.That is because Apellis is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat. After all, analysts raising estimates right before earnings — with the most up-to-date information possible — is a pre ...

Investors might want to bet on Apellis Pharmaceuticals, Inc. (APLS) , as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following ...

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Apellis Pharmaceuticals, Inc. (APLS) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.Apellis Pharmaceuticals, Inc. is one of 1071 companies in the Medical group. The Medical group currently sits at #5 within the Zacks Sector Rank. The Zacks Sector Rank gauges the ...

The market expects Apellis Pharmaceuticals, Inc. (APLS) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2023. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The earnings report might help the stock move higher if these key numbers are better than expectations. On the ...